- Home
- DXLG vs CUE Comparison
DXLG vs CUE Comparison
Compare DXLG & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DXLG | CUE |
|---|---|---|
| Founded | 1976 | 2014 |
| Country | United States | United States |
| Employees | N/A | 41 |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.2M | 27.8M |
| IPO Year | 1994 | 2017 |
Fundamental Metrics
Financial Performance| Metric | DXLG | CUE |
|---|---|---|
| Price | $0.49 | $0.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $2.50 | ★ $3.00 |
| AVG Volume (30 Days) | 110.8K | ★ 442.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 35.14 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $467,015,000.00 | $9,287,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.24 | $25.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 69.16 |
| 52 Week Low | $0.47 | $0.23 |
| 52 Week High | $2.07 | $1.05 |
Technical Indicators
Market Signals| Indicator | DXLG | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 38.04 | 39.65 |
| Support Level | N/A | $0.27 |
| Resistance Level | $0.57 | $0.36 |
| Average True Range (ATR) | 0.05 | 0.03 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 12.09 | 14.60 |
Price Performance
Historical ComparisonAbout DXLG Destination XL Group Inc.
Destination XL Group Inc is a retailer of branded and Tall men's clothing and shoes in the United States. It also sells products across the world. The company sells its products under the trade names Destination XL, DXL, DXL Men's Apparel, DXL outlets, Casual Male XL, and Casual Male XL outlets. The company has two principal operating segments: Store, and Direct business.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.